

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Soppet et al.

Attorney Docket No.: PZ037P1C1

Application Serial No.: Unassigned

Art Unit: Unassigned

Filed: Herewith

Examiner: Unassigned

Title: 33 Human Secreted Proteins

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to the prosecution of the above-captioned application, please enter the following amendments. Applicants submit concurrently herewith a copy of the Petition for Extension of Time for one (1) month under 37 C.F.R. § 1.136 ("Petition") filed in connection with the parent application, Serial No. 09/628,508, which extends the time for reply in the parent from November 2, 2001 to and including December 3, 2001 (December 2 is a Sunday). This Petition evidences copendency between parent application Serial No. 09/628,508 and the present application.

Amendments

In the Specification

Please replace the first paragraph on page 1 with the following paragraph:

This application is a continuation application of U.S. Application No. 09/628,508, filed July 28, 2000, which is hereby incorporated by reference in its entirety, which is a continuation-in-part of, and claims benefit under 35 U.S.C. § 120 of copending PCT International Application Serial No. PCT/US00/03062, filed February 8, 2000, and published in the English language, which is hereby incorporated by reference, which claims benefit under 35 U.S.C. § 119(e) based on U.S. Provisional Application No. 60/119,468 filed February 10, 1999, which is hereby incorporated by reference.

In the Claims

Please enter the following amended claim 17:

17. (Amended) A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11.

Please add the following claim:

24. (New) A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polynucleotide of claim 1.

REMARKS

The specification has been amended to add priority information. The claims have been amended to more particularly point out and distinctly claim the subject matter Applicants regard as the invention. Support for new claim 24 can be found throughout the application as filed. Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

No new matter has been introduced.

Applicants believe that no fee is required for this submission. However, should a fee be due, please charge such fee to Deposit Account No. 08-3425.

Respectfully submitted

Date: NOVEMBER 30, 2001


Janet M. Martineau (Reg. No. 46,903)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 315-2723

KKH/JMM/CAW/ba

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Soppet et al.

Atty. Docket No.: PZ037P1C1

Application Serial No.: Unassigned

Art Unit: Unassigned

Filed: Herewith

Examiner: Unassigned

For: 33 Human Secreted Proteins

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification

The first paragraph on page 1 has been amended as follows:

This application is a continuation application of U.S. Application No. 09/628,508, filed July 28, 2000, which is hereby incorporated by reference in its entirety, which [This application] is a continuation-in-part of, and claims benefit under 35 U.S.C. § 120 of copending PCT International Application Serial No. PCT/US00/03062, filed February 8, 2000, and published in the English language, which is hereby incorporated by reference, which claims benefit under 35 U.S.C. § 119(e) based on U.S. Provisional Application No. 60/119,468 filed February 10, 1999, which is hereby incorporated by reference.

In the Claims:

Claim 17 has been amended as follows:

17. (Amended) A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 [or the polynucleotide of claim 1].